Indications and options of new immune modulatory therapies for Sjögren's syndrome;Indikation und option neuer immunmodulatorischer therapien beim Sjögren-syndrom

Zeitschrift fur Rheumatologie

Volumn 66, Issue 8, 2007, Pages 679-685

  Feist, E ^a,b   Dorner T ^a,b   Hansen, A ^a,b  

^a Interdisziplinäres Sjögren Syndrom Centrum   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

B cell targeting therapy; Biologicals; Connective tissue diseases; Sj gren's syndrome

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

B LYMPHOCYTE; DISEASE ACTIVITY; DISEASE COURSE; HODGKIN DISEASE; HUMAN; PALLIATIVE THERAPY; PATHOGENESIS; REVIEW; SJOEGREN SYNDROME; SYMPTOMATOLOGY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SJOGREN'S SYNDROME; T-LYMPHOCYTES;

EID: 37449008337     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-007-0231-z     Document Type: Review

References (35)

1. Kassan SS, Moutsopoulos HM (2004) Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 164: 1275-1284
2. Vitali C, Bombardieri S, Jonsson R et al. European Study Group on Classification Criteria for Sjogren's Syndrome (2002) Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554-558
3. Fox RI (2005) Sjögren's syndrome. Lancet 366: 321-331
4. Hansen A, Lipsky PE, Dorner T (2005) Immunopathogenesis of primary Sjogren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 17: 558-565
5. Nakamura H, Kawakami A, Tominaga M et al. (2000) Relationship between Sjogren's syndrome and human T-lymphotropic virus type I infection: follow-up study of 83 patients. J Lab Clin Med 135: 139-144
6. Triantafyllopoulou A, Tapinos N, Moutsopoulos HM (2004) Evidence for coxsackievirus infection in primary Sjögren's syndrome. Arthritis Rheum 50: 2897-2902
7. Steinfeld SD, Demols P, Salmon I et al. (2001) Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 44: 2371-2375
8. Mariette X, Ravaud P, Steinfeld S et al. (2004) Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 50: 1270-1276
9. Sankar V, Brennan MT, Kok MR et al. (2004) Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50: 2240-2245
10. Zandbelt MM, Wilde P de, Damme P van et al. (2004) Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J Rheumatol 31: 96-101
11. Mavragani CP, Niewold TB, Moutsopoulos NM et al. (2006) Exagerration of interferon-alpha pathway and BAFF production in patients with Sjogren's syndrome after anti-TNF treatment. ACR-Meeting, 684
12. Cummins MJ, Papas A, Kammer GM, Fox PC (2003) Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 49: 585-593
13. Nordmark G, Alm GV, Ronnblom L (2006) Mechanisms of disease: primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol 2: 262-269
14. Yamada S, Mori K, Matsuo K et al. (2005) Interferon alfa treatment for Sjogren's syndrome associated neuropathy. J Neurol Neurosurg Psychiatry 76: 576-578
15. http://www.clinicaltrials.gov
16. Lipsky PE (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2: 764-766
17. Hansen A, Lipsky PE, Dorner T (2007) B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol 3: 561-569
18. Dorner T (2006) Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl 77: 3-11
19. Cacoub P, Delluc A, Saadoun D et al. (in press) Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemia vasculitis: where do we stand? Ann Rheum Dis 20: Epub ahead of print
20. Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165: 2337-2344
21. Pijpe J, Imhoff GW van, Spijkervet FK et al. (2005) Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52: 2740-2750
22. Seror R, Sordet C, Guillevin L et al. (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 66: 351-357
23. Gottenberg JE, Guillevin L, Lambotte O et al. Club Rheumatismes et Inflammation (CRI) (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64: 913-920
24. Pijpe J, Imhoff GW van, Vissink A et al. (2005) Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis 64: 958-960
25. Meijer JM, Pijpe J, Imhoff GW van et al. (2006) ACR-Meeting, 526
26. Tedder TF, Poe JC, Haas KM (2005) CD22: A multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 88: 1-50
27. Dorner T, Kaufmann J, Wegener WA et al. (2006) Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8: R74
28. Steinfeld SD, Tant L, Burmester GR et al. (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 8: R129
29. Sutherland AP, Mackay F, Mackay CR (2006) Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 112: 774-786
30. Groom J, Kalled SL, Cutler AH et al. (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109: 59-68
31. Keystone EB (2005) Cell targeted therapies. Arthritis Res Ther (Suppl 3) 7: S13-S18
32. Hennessy BT, Hanrahan EO, Daly PA (2004) Non-Hodgkin lymphoma: an update. Lancet Oncol 5: 341-353
33. Wada K, Kamitani T (2006) Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res Commun 339: 415-421
34. Espinosa A, Zhou W, Ek M et al. (2006) The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 176: 6277-6285
35. Teplova M, Yuan YR, Phan AT et al. (2006) Structural basis for recognition and sequestration of UUU(OH) 3' temini of nascent RNA polymerase III transcripts by La, a rheumatic disease autoantigen. Mol Cell 21: 75-85